Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ezogabine

FDA-approved product (tablet, oral), marketed as Potiga.

Registered studies
32
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ezogabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Epilepsy
  • Seizure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiepileptics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

32registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ezogabine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ezogabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures

    NCT01648101 · start 2012-08-29

    Registered record
    Registry ID
    NCT01648101
    Conditions
    Epilepsy
    Interventions
    Retigabine 900mg/day; Retigabine 600mg/day; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-08-29
    Completion
    2013-12-23
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionRetigabine 900mg/day; Retigabine 600mg/day; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Study in Pediatric Subjects With Epilepsy

    NCT01494584 · start 2012-07-25

    Registered record
    Registry ID
    NCT01494584
    Conditions
    Epilepsy
    Interventions
    ezogabine/retigabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-07-25
    Completion
    2013-04-29
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    Interventionezogabine/retigabine
    PhasePhase 2
    Registry statusTerminated

  • Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects

    NCT01462669 · start 2012-04-10

    Registered record
    Registry ID
    NCT01462669
    Conditions
    Epilepsy
    Interventions
    50mg Ezogabine/retigabine; 100mg Ezogabine/retigabine; 200mg Ezogabine/retigabine; 400mg Ezogabine/retigabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04-10
    Completion
    2012-06-27
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    Intervention50mg Ezogabine/retigabine; 100mg Ezogabine/retigabine; 200mg Ezogabine/retigabine; 400mg Ezogabine/retigabine
    PhasePhase 1
    Registry statusCompleted

  • An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed

    NCT01583036 · start 2012-01-16

    Registered record
    Registry ID
    NCT01583036
    Conditions
    Epilepsy
    Interventions
    Digoxin Alone; Digoxin + Retigabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-01-16
    Completion
    2012-04-17
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionDigoxin Alone; Digoxin + Retigabine
    PhasePhase 1
    Registry statusCompleted

  • Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite

    NCT01480609 · start 2011-11-30

    Registered record
    Registry ID
    NCT01480609
    Conditions
    Epilepsy
    Interventions
    Retigabine / Ezogabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11-30
    Completion
    2012-04-24
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionRetigabine / Ezogabine
    PhasePhase 1
    Registry statusCompleted

  • Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304

    NCT01457989 · start 2011-08

    Registered record
    Registry ID
    NCT01457989
    Conditions
    Epilepsy, Partial
    Interventions
    retigabine/ezogabine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-08
    Completion
    2011-08
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy, Partial
    Interventionretigabine/ezogabine
    PhaseNot recorded
    Registry statusCompleted

  • Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)

    NCT01336621 · start 2011-02-21

    Registered record
    Registry ID
    NCT01336621
    Conditions
    Epilepsy
    Interventions
    Retigabine IR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-02-21
    Completion
    2017-09-13
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionRetigabine IR
    PhasePhase 3
    Registry statusCompleted

  • An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

    NCT01332513 · start 2011-02-10

    Registered record
    Registry ID
    NCT01332513
    Conditions
    Epilepsy
    Interventions
    Investigational Medicinal Product (MR1); Investigational Medicinal Product (MR2); Investigational Medicinal Product (MR3); Investigational Medicinal Product (MR4); Investigational Medicinal Product (MR5); Investigational Medicinal Product (IR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02-10
    Completion
    2011-05-23
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionInvestigational Medicinal Product (MR1); Investigational Medicinal Product (MR2); Investigational Medicinal Product (MR3); Investigational Medicinal Product (MR4) +2 more
    PhasePhase 1
    Registry statusCompleted

  • Risk of Urinary Retention With Retigabine

    NCT01462656 · start 2011-02

    Registered record
    Registry ID
    NCT01462656
    Conditions
    Epilepsy
    Interventions
    Non-EZG containing AED polytherapy; EZG containing AED polytherapy; Non-EZG AED monotherapy; EZG AED monotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2011-02
    Completion
    2016-08
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionNon-EZG containing AED polytherapy; EZG containing AED polytherapy; Non-EZG AED monotherapy; EZG AED monotherapy
    PhaseNot recorded
    Registry statusTerminated

  • Bioavailability of Different n-3 Fatty Acid Formulations

    NCT01214278 · start 2010-10

    Registered record
    Registry ID
    NCT01214278
    Conditions
    Health
    Interventions
    rTG; GArTG; EE; KPL
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-10
    Completion
    2011-07
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealth
    InterventionrTG; GArTG; EE; KPL
    PhasePhase 4
    Registry statusCompleted

  • Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

    NCT01587339 · start 2010-09

    Registered record
    Registry ID
    NCT01587339
    Conditions
    Epilepsy
    Interventions
    retigabine/ezogabine; lacosamide; zonisamide; pregabalin; eslicarbazepine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-09
    Completion
    2011-07
    Enrolment
    6,498

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    Interventionretigabine/ezogabine; lacosamide; zonisamide; pregabalin +1 more
    PhaseNot recorded
    Registry statusCompleted

  • Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures

    NCT01227902 · start 2010-07

    Registered record
    Registry ID
    NCT01227902
    Conditions
    Epilepsy
    Interventions
    Retigabine IR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-07
    Completion
    2012-12
    Enrolment
    203

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionRetigabine IR
    PhasePhase 3
    Registry statusCompleted

  • Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

    NCT00612105 · start 2007-10

    Registered record
    Registry ID
    NCT00612105
    Conditions
    Postherpetic Neuralgia
    Interventions
    Retigabine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-10
    Completion
    2009-12
    Enrolment
    187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostherpetic Neuralgia
    InterventionRetigabine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097

    NCT00310388 · start 2006-07-05

    Registered record
    Registry ID
    NCT00310388
    Conditions
    Epilepsy
    Interventions
    Retigabine (INN), Ezogabine (USAN)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-07-05
    Completion
    2018-05-24
    Enrolment
    376

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionRetigabine (INN), Ezogabine (USAN)
    PhasePhase 3
    Registry statusTerminated

  • Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

    NCT00310375 · start 2006-05-01

    Registered record
    Registry ID
    NCT00310375
    Conditions
    Epilepsy
    Interventions
    Ezogabine: USAN Retigabine (International Nonproprietary Name)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-05-01
    Completion
    2017-03-15
    Enrolment
    181

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionEzogabine: USAN Retigabine (International Nonproprietary Name)
    PhasePhase 3
    Registry statusCompleted